Pancreatic secretory trypsin inhibitor from human amniotic fluid and fetal and neonatal urine: concentrations and physicochemical characterization.
The levels and physicochemical properties of the pancreatic secretory trypsin inhibitor, also known as Kazal type trypsin inhibitor, were studied in human amniotic fluid. In the second trimester, the median concentration was 160 ng/ml, which exceeds the maternal serum levels 20-fold. Towards term, the amniotic fluid levels declined about 5-fold, whereas the maternal serum values remained constant. In fetal urine, the concentration of the trypsin inhibitor was similar to that in amniotic fluid in early gestation, whereas in newborn urine, the median level was 4-to 5-fold higher than in term amniotic fluid. The physiochemical characteristics of the trypsin inhibitor in amniotic fluid, neonatal urine and cancer urine from an ovarian cancer patient were similar, as studied by gel filtration, high performance reverse phase liquid chromatography, and complete immunological identity in immunodiffusion. The physicochemical similarity and levels in various compartments suggest fetal contribution to amniotic fluid levels of the trypsin inhibitor.
D000653:Amniotic Fluid / Q000032:analysis*; D002850:Chromatography, Gel; D002851:Chromatography, High Pressure Liquid; D005312:Fetal Blood / Q000032:analysis; D005333:Fetus / Q000378:metabolism*; D005865:Gestational Age; D006801:Humans; D005779:Immunodiffusion; D007231:Infant, Newborn; D014359:Trypsin Inhibitor, Kazal Pancreatic / Q000032:analysis* / Q000097:blood / Q000652:urine; D014361:Trypsin Inhibitors / Q000032:analysis*
D014361:Trypsin Inhibitors; D014359:Trypsin Inhibitor, Kazal Pancreatic